TY - JOUR
T1 - Colorectal Cancer Liver Metastasis
T2 - Evolving Paradigms and Future Directions
AU - Zarour, Luai R.
AU - Anand, Sudarshan
AU - Billingsley, Kevin G.
AU - Bisson, William H.
AU - Cercek, Andrea
AU - Clarke, Michael F.
AU - Coussens, Lisa M.
AU - Gast, Charles E.
AU - Geltzeiler, Cristina B.
AU - Hansen, Lissi
AU - Kelley, Katherine A.
AU - Lopez, Charles D.
AU - Rana, Shushan R.
AU - Ruhl, Rebecca
AU - Tsikitis, V. Liana
AU - Vaccaro, Gina M.
AU - Wong, Melissa H.
AU - Mayo, Skye C.
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/3/1
Y1 - 2017/3/1
N2 - In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.
AB - In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver. Our multidisciplinary group held a state-of-the-science symposium this past year to review advances in this rapidly evolving field. Herein, we present a discussion around the issues facing treatment of patients with CRC liver metastases, including the relationship of discrete gene signatures with prognosis. We also discuss the latest advances to maximize regional and systemic therapies aimed at decreasing intrahepatic recurrence, review recent insights into the tumor microenvironment, and summarize advances in noninvasive multimodal biomarkers for early detection of primary and recurrent disease. As we continue to advance clinically and technologically in the field of colorectal tumor biology, our goal should be continued refinement of predictive and prognostic studies to decrease recurrence after curative resection and minimize treatment toxicity to patients through a tailored multidisciplinary approach to cancer care.
KW - Biomarkers
KW - Colorectal Cancer Liver Metastasis
KW - Hepatic Arterial Infusion
KW - High-Risk Colorectal Cancer
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85014082003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014082003&partnerID=8YFLogxK
U2 - 10.1016/j.jcmgh.2017.01.006
DO - 10.1016/j.jcmgh.2017.01.006
M3 - Review article
AN - SCOPUS:85014082003
SN - 2352-345X
VL - 3
SP - 163
EP - 173
JO - Cellular and Molecular Gastroenterology and Hepatology
JF - Cellular and Molecular Gastroenterology and Hepatology
IS - 2
ER -